Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Abstract PD-1/PD-L1 blockade has so far shown limited survival benefit for high-grade ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II trial (NCT03275506), for which primary outcomes are published, and by combining RNA-seq and multiplexed immunofluorescence stainin...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, Justine Cinier, Yasmine Lounici, Isabelle Treilleux, Pierre-Alexandre Just, Guillaume Bataillon, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Elodie Coquan, Olfa Derbel, Louis Jeay, Suliman Bouizaguen, Intidhar Labidi-Galy, Séverine Tabone-Eglinger, Anthony Ferrari, Emilie Thomas, Christine Ménétrier-Caux, Eric Tartour, Isabelle Galy-Fauroux, Marc-Henri Stern, Magali Terme, Christophe Caux, Bertrand Dubois, Isabelle Ray-Coquard
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Nature Portfolio 2024-07-01
Seri Bilgileri:	Nature Communications
Online Erişim:	https://doi.org/10.1038/s41467-024-47000-5
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Benzer Materyaller